HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on X4 Pharmaceuticals (NASDAQ:XFOR) and maintained a $3 price target.

March 22, 2024 | 6:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on X4 Pharmaceuticals with a $3 price target.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on X4 Pharmaceuticals' stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to stock price movements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100